NASDAQ:CRDF Cardiff Oncology (CRDF) Stock Price, News & Analysis $0.96 -0.02 (-2.13%) Closing price 04:00 PM EasternExtended Trading$1.00 +0.04 (+3.84%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Cardiff Oncology Stock (NASDAQ:CRDF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cardiff Oncology alerts:Sign Up Key Stats Today's Range$0.96▼$1.0250-Day Range$0.81▼$1.5952-Week Range$0.76▼$3.31Volume481,026 shsAverage Volume1.20 million shsMarket Capitalization$74.91 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingHold Company Overview Cardiff Oncology, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments. Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development. These candidates target pathways implicated in tumor immune evasion, with the goal of inducing immunogenic cell death and improving response rates. The company’s strategic approach emphasizes combination regimens, pairing its agents with established immunotherapies to potentially increase efficacy in solid tumors. Since its founding in 2015, Cardiff Oncology has pursued strategic collaborations to accelerate its programs, notably entering a research agreement with Merck & Co. to explore combination studies with pembrolizumab. The company conducts its clinical trials across multiple sites in the United States and internationally, serving a global oncology community committed to developing new therapeutic options for patients with cancer.AI Generated. May Contain Errors. Read More Cardiff Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCRDF MarketRank™: Cardiff Oncology scored higher than 60% of companies evaluated by MarketBeat, and ranked 367th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingCardiff Oncology has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 2 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialCardiff Oncology has a consensus price target of $7.50, representing about 678.8% upside from its current price of $0.96.Amount of Analyst CoverageCardiff Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cardiff Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cardiff Oncology are expected to decrease in the coming year, from ($0.66) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiff Oncology is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiff Oncology is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cardiff Oncology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.45% of the float of Cardiff Oncology has been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 9.26.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 0.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment-0.51 News SentimentCardiff Oncology has a news sentiment score of -0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cardiff Oncology this week, compared to 3 articles on an average week.Search Interest7 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows2 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership4.1 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Cardiff Oncology in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $66,491.00 in company stock, which represents 0.0888% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $66,491.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders8.50% of the stock of Cardiff Oncology is held by insiders.Percentage Held by Institutions16.29% of the stock of Cardiff Oncology is held by institutions.Read more about Cardiff Oncology's insider trading history. Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRDF Stock News HeadlinesCardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business UpdateAugust 12 at 9:04 AM | finanznachrichten.deCardiff Oncology Reports Second Quarter 2026 Results and Provides Business UpdateAugust 11 at 4:10 PM | globenewswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.August 14 at 1:00 AM | Porter & Company (Ad)Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $7.50 Average PT from BrokeragesAugust 4, 2026 | americanbankingnews.comCardiff Oncology announces $10M direct offeringJuly 16, 2026 | msn.comCardiff Oncology Announces $10 Million Registered Direct OfferingJuly 15, 2026 | globenewswire.comCRDF: Phase II update; survival advantage extendedJune 22, 2026 | msn.comCardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer TranscriptJune 3, 2026 | seekingalpha.comSee More Headlines CRDF Stock Analysis - Frequently Asked Questions How have CRDF shares performed this year? Cardiff Oncology's stock was trading at $2.81 at the beginning of 2026. Since then, CRDF shares have decreased by 65.7% and is now trading at $0.9630. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) issued its earnings results on Tuesday, August, 11th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.06 million. Cardiff Oncology had a negative net margin of 7,885.43% and a negative trailing twelve-month return on equity of 93.24%. Who are Cardiff Oncology's major shareholders? Top institutional investors of Cardiff Oncology include BlackRock Inc. (1.42%), Flputnam Investment Management Co. (0.36%), X Square Capital LLC (0.30%) and GSA Capital Partners LLP (0.25%). Insiders that own company stock include Gary W Pace and Mani Mohindru. View institutional ownership trends. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/11/2026Today8/14/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CRDF's financial health is in the Red zone, according to TradeSmith. CRDF has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRDF CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees20Year Founded1999Price Target and Rating Average Price Target for Cardiff Oncology$7.50 High Price Target$12.00 Low Price Target$2.00 Potential Upside/Downside+678.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.85 million Net Margins-7,885.43% Pretax Margin-8,526.09% Return on Equity-93.24% Return on Assets-68.74% Debt Debt-to-Equity RatioN/A Current Ratio3.27 Quick Ratio3.27 Sales & Book Value Annual Sales$590 thousand Price / Sales126.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book1.44Miscellaneous Outstanding Shares77,790,000Free Float62,679,000Market Cap$74.91 million OptionableOptionable Beta1.49 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CRDF) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredLeading AI Insider Issues Urgent Market WarningA leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...TradeSmith | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredHuge AI Announcement Coming on September 3A $51 billion backlog, a SpaceX partnership, and a presidential endorsement are fueling renewed attention on t...InvestorPlace | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDF Stock Alerts